{
    "relation": [
        [
            "",
            "Mothers ATV 300 mg / 100 mg Second Trimester",
            "Mothers ATV 300 mg / 100 mg Third Trimester",
            "Mothers ATV 400 mg / 100 mg Third Trimester"
        ],
        [
            "Description",
            "Mothers receiving ATV/RTV 300/100 mg QD + ZDV/3TC 300/150 mg BID during weeks 12 to 28 of pregnancy. Each dose of ATV/RTV (taken with a light meal or snack) was taken approximately 24 hours apart. Each dose of ZDV/3TC (taken with or without food) was taken approximately 12 hours apart.",
            "Mothers receiving ATV/RTV 300/100 mg QD + ZDV/3TC 300/150 mg BID during weeks 28 to 38 of pregnancy. Each dose of ATV/RTV (taken with a light meal or snack) was taken approximately 24 hours apart. Each dose of ZDV/3TC (taken with or without food) was taken approximately 12 hours apart.",
            "Mothers receiving ATV/RTV 400/100 mg QD + ZDV/3TC 300/150 mg BID during weeks 28 to 36 of pregnancy. Each dose of ATV/RTV (taken with a light meal or snack) was taken approximately 24 hours apart. Each dose of ZDV/3TC (taken with or without food) was taken approximately 12 hours apart."
        ]
    ],
    "pageTitle": "Pharmacokinetics of Atazanavir/Ritonavir in HIV-1 Infected Pregnant Women - Study Results - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/ct2/show/results/NCT00326716?sect=Xi015&view=results",
    "hasHeader": true,
    "headerPosition": "MIXED",
    "tableType": "RELATION",
    "tableNum": 25,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042989234.2/warc/CC-MAIN-20150728002309-00342-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 859880854,
    "recordOffset": 859864915,
    "tableOrientation": "HORIZONTAL",
    "textBeforeTable": "Reporting Groups Of the 69 enrolled participants, 28 mothers were not treated. Failure to continue to meet enrollment criteria resulting in discontinuation in 24/28 participants and 4 were not treated: 1 poor/no compliance, 1 met exclusion criteria, 1 was ARV naive subject with HIV RNA < 400 c/mL, and 1 was unable to comply with study procedures. Significant events and approaches for the overall study following participant enrollment, but prior to group assignment Pre-Assignment Details Pregnant participants were enrolled at 6 sites: United States (2), South Africa (3), and Puerto Rico (1). Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations Recruitment Details \u00a0 Hide Participant Flow \u00a0 Participant Flow Drug: Atazanavir + Ritonavir + Combivir Intervention: HIV Infection",
    "textAfterTable": "Infants ATV 400 mg / RTV 100 mg Infants born to mothers receiving treatment with ATV 400 mg / RTV 100 mg during the third trimester of pregnancy. Participant Flow for 2 periods Period 1: \u00a0 Pre-Natal Mothers \u00a0 \u00a0 Mother ATV 300 mg / RTV 100 mg \u00a0 \u00a0 Mother ATV 400 mg / RTV 100 mg \u00a0 \u00a0 Infants ATV 300 mg / RTV 100 mg \u00a0 \u00a0 Infants ATV 400 mg / RTV 100 mg \u00a0 STARTED \u00a0 \u00a0 20 \u00a0 \u00a0 21 \u00a0 \u00a0 0 \u00a0 \u00a0 0 \u00a0 COMPLETED \u00a0 \u00a0 19 [1] \u00a0 19 [1] \u00a0 0 [2] \u00a0 0 [2] NOT COMPLETED \u00a0",
    "hasKeyColumn": true,
    "keyColumnIndex": 0,
    "headerRowIndex": 0
}